95 related articles for article (PubMed ID: 10419050)
21. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
22. Adeno-retroviral chimeric viruses as in vivo transducing agents.
Caplen NJ; Higginbotham JN; Scheel JR; Vahanian N; Yoshida Y; Hamada H; Blaese RM; Ramsey WJ
Gene Ther; 1999 Mar; 6(3):454-9. PubMed ID: 10435096
[TBL] [Abstract][Full Text] [Related]
23. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
24. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
26. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo MJ; Maguire HC; Eisenlohr LC; Laughlin CE; Monken CE; McCue PA; Kovatich AJ; Lattime EC
Cancer Gene Ther; 1999; 6(5):409-22. PubMed ID: 10505851
[TBL] [Abstract][Full Text] [Related]
29. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
30. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus and retrovirus mediated interferon alpha gene transfer into CD34+ cells maintains regeneration capacity and enhances adhesion molecules in K562 cells.
Seiter K; Kancherla R; Yang L; Quan S; Farley TJ; Abraham NG; Ahmed T
J Investig Med; 1999 Sep; 47(8):414-24. PubMed ID: 10510594
[TBL] [Abstract][Full Text] [Related]
33. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
35. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Duval L; Schmidt H; Kaltoft K; Fode K; Jensen JJ; Sorensen SM; Nishimura MI; von der Maase H
Clin Cancer Res; 2006 Feb; 12(4):1229-36. PubMed ID: 16489078
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
Tait DL; Obermiller PS; Hatmaker AR; Redlin-Frazier S; Holt JT
Clin Cancer Res; 1999 Jul; 5(7):1708-14. PubMed ID: 10430073
[TBL] [Abstract][Full Text] [Related]
37. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
Walther W; Siegel R; Kobelt D; Knösel T; Dietel M; Bembenek A; Aumann J; Schleef M; Baier R; Stein U; Schlag PM
Clin Cancer Res; 2008 Nov; 14(22):7545-53. PubMed ID: 19010873
[TBL] [Abstract][Full Text] [Related]
38. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.
Tait DL; Obermiller PS; Redlin-Frazier S; Jensen RA; Welcsh P; Dann J; King MC; Johnson DH; Holt JT
Clin Cancer Res; 1997 Nov; 3(11):1959-68. PubMed ID: 9815585
[TBL] [Abstract][Full Text] [Related]
40. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]